use of, information about cancer across the cancer care continuum from cancer prevention, early detection, diagnosis, treatment, and survivorship. The content of the survey will focus on understanding the degree to which members of the general population understand vital cancer prevention messages. More importantly, this NCI

survey will couple knowledge-related questions with inquiries into the communication channels through which understanding is being obtained, and assessment of cancer-related behavior. The Public Health Services Act, Sections 411 (42 U.S.C. 285a) and 412 (42 U.S.C. 285a-1.1 and 285a-1.3), outline the research and information

dissemination mission of the NCI which authorizes the collection of this information. Frequency of Response: Once. Affected Public: Individuals. Type of Respondents: U.S. adults (persons aged 18+). The annual reporting burden is documented in the table below. There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Data collection cycle	Type of respondent	Number of respondents	Frequency of response	Average time per response minutes/ hour	Annual hour burden
Cycle 1	Mail survey	3,533	1	30/60 (.5)	1,766.5
Cycle 2	Mail survey	3,533	1	30/60 (.5)	1,766.5
Cycle 3	Mail survey	3,500	1	30/60 (.5)	1,750
Cycle 4	Mail survey	3,500	1	30/60 (.5)	1,750
Total					7,033

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs,

OIRA\_submission@omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer, Office of Management and Budget, at

OIRA\_submission@omb.eop.gov or by fax to 202–395–6974. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Bradford W. Hesse, PhD, Project Officer, National Cancer Institute, NIH, EPN 4068, 6130 Executive Boulevard, MSC 7365, Bethesda, Maryland 20892–7365, or call non-toll free number 301–594–9904 or fax your request to 301–480–2198, or email your request, including your address, to hesseb@mail.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: June 20, 2011.

### Vivian Horovitch-Kelley,

NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2011–15994 Filed 6–24–11; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources, biologics, clinical assays and other developmental programs for potential new therapeutics for the treatment of cancer. The outcome of the evaluation

will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Clinical Assay Development Program (CADP).

Date: July 27, 2011.

Time: 9 a.m.-4 p.m.

Agenda: To review grant applications for the CADP.

Place: Bethesda Marriott North Hotel, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Dr. Barbara Conley, Executive Secretary, Clinical Assay Development Program (CADP), National Cancer Institute, NIH, 6130 Executive Boulevard, Room 6035A, Bethesda, MD 20892, 301–496–8639,

conleyba@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: June 21, 2011.

#### Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011-15997 Filed 6-24-11; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, July 7, 2011, 8 a.m. to July 8, 2011, 5 p.m., Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852 which was published in the **Federal Register** on May 16, 2011, 76FR28236.

This notice is amending the dates and times of the meeting from July 7–8, 2011, 8 a.m. to 5 p.m. to the following dates and times: July 6th—7:30 to 10 p.m., July 7th—8 a.m. to 5 p.m., and July 8th—8 a.m. to 4 p.m. The meeting is closed to the public.

Dated: June 21, 2011.

### Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–15999 Filed 6–24–11; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

## National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Core Infrastructure and Methological Research for Cancer Epidemiology Cohorts,

Date: July 12, 2011,

Time: 8 a,m, to 5 p,m

Agenda: To review and evaluate grant applications.

*Place:* Lorien Hotel and Spa, 1600 King Street, Alexandria, VA 22314.

Contact Person: Marvin L. Salin, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892–8329, 301–496–0694, msalin@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Melanoma P01.

Date: July 13, 2011.

Time: 12:30 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Cancer Institute, 6116 Executive Blvd, Room 8018, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Delia Tang, M.D., Scientific Review Officer, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8123, MSC 8328, Bethesda, MD 20892, 301–496–2330, tangd@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Small Grants Program for Cancer Epidemiology.

Date: July 21–22, 2011.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Legacy Hotel and Meeting Center,
1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Joyce C. Pegues, B.S., B.A., Ph..D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, NIH National Cancer Institute, 6116 Executive Boulevard, Room 7149, Bethesda, MD 20892–8329, 301–594–1286, peguesj@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (P20).

Date: July 28–29, 2011.

Time: 8 a.m. to 5 p.m

*Agenda:* To review and evaluate grant applications.

Place: Marriott Bethesda North Conference & Center, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Clifford W Schweinfest, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8050a, Bethesda, MD 20892–8329, 301–402–9415, schweinfestcw@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: June 21, 2011.

#### Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011-16000 Filed 6-24-11; 8:45 am]

BILLING CODE 4140-01-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Council of Councils.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended because the premature disclosure of grant applications and the discussions would likely to significantly frustrate implementation of recommendations.

Name of Committee: Council of Councils. Date: August 15, 2011.

Open: 1 p.m. to 2: p.m.

Agenda: Discussion of NIH Director's Early Independence Awards program and review process. See: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-10-019.html. Dial-in number: 866–695–1528. Conference code: 6971723704

Place: National Institutes of Health, Building 1, 1 Center Drive, Room 260, Bethesda, MD 20892, (Telephone Conference Call).

Closed: 2 p.m. to 4 p.m.

Agenda: To review and evaluate secondlevel review of NIH Director's Early Independence Awards grant applications.

Place: National Institutes of Health, Building 1, 1 Center Drive, Room 260, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Robin Kawazoe, Executive Secretary, Division of Program Coordination, Planning, and Strategic Initiatives, Office Of The Director, NIH, Building 1, ROOM 260B, Bethesda, MD 20892,

KAWAZOER@mail.nih.gov.

Additional information, including the meeting agenda is available on the Council of Council's home page: http://dpcpsi.nih.gov/council/.

Any interested person may file written comments with the committee by forwarding